Loading…
Iqvia Holdings Inc
Iqvia Holdings Inc (IQV) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Durham, United States and has 94,000 employees. The company is worth $45.81B and trades at 34.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $16.31B in fiscal 2025, up 5.9% from the year before. Net income was $1.36B. The share price is within 3% of its 52-week high. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $296.95M. In that quarter, 3 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +3.0% over 5Y.
today you would have $1,020.96▲ +2.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 13 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $225.41 | $196.51 | $231.38 | $204.89 | $282.14 | $179.17 | $154.51 | $116.17 | $97.90 | $76.05 | $68.66 | $58.87 | $46.34 | |
| P/E | 31.7x | 28.8x | 26.2x | 31.7x | 35.8x | 57.0x | 125.3x | 160.9x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 31.7 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HLNHaleon plc | $10.37 | 21.2x | 2.1x | 1.93% | 10.09% | $45.6B |
| TEVATEVA Pharmaceutical Industries Ltd | $40.21 | 67.0x | 6.0x | 0.00% | 9.69% | $46.9B |
| WATWaters Corp | $455.59 | 115.9x | 2.9x | 0.00% | 1.92% | $44.73B |
| MDLNMedline Inc. | $34.88 |
| 93.7x |
| 17.1x |
| 161.8x |
| 22.3x |
| 21.6x |
| 26.2x |
| P/S | 2.3x | 2.3x | 2.2x | 2.8x | 2.6x | 3.9x | 3.0x | 2.7x | 2.2x | 2.1x | 2.6x | 1.4x | 1.3x | 1.2x |
| P/B | 5.7x | 5.9x | 5.7x | 6.9x | 6.6x | 8.9x | 5.7x | 5.0x | 3.4x | 2.6x | 2.1x | — | — | — |
| EPS | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 | $3.08 | $2.72 | $1.77 |
| Profit margin | 6.75% | 8.34% | 8.91% | 9.06% | 7.57% | 6.96% | 2.46% | 1.72% | 2.49% | 13.11% | 1.05% | 6.75% | 6.54% | 4.44% |
| ROE | 15.98% | 20.91% | 22.63% | 22.22% | 18.92% | 15.99% | 4.65% | 3.18% | 3.86% | 15.97% | 0.83% | — | — | — |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-14.8% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 87.2x |
| 2.6x |
| 0.00% |
| 4.93% |
| $46.93B |
| IDXXIdexx Laboratories Inc | $566.76 | 39.8x | 27.7x | 0.00% | 74.21% | $44.65B |
| ONCBeOne Medicines Ltd. | $382.27 | 69.1x | 8.4x | 0.00% | 14.66% | $43.49B |
